European Commission Approves Merck’s Anti-PD-1 Therapy, KEYTRUDA® (pembrolizumab), for Both First-line and Previously-treated Patients with Advanced Melanoma

Dateline City:

KENILWORTH, N.J.

KEYTRUDA Demonstrated Superior Survival versus Ipilimumab in a Phase 3 Clinical Trial

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the European Commission has approved KEYTRUDA®
(pembrolizumab), the company’s anti-PD-1 therapy, for the treatment of
advanced (unresectable or metastatic) melanoma in adults. The European
Commission approval of KEYTRUDA is based on data from three clinical
studies conducted in more than 1,500 first-line and previously-treated
patients with advanced melanoma.
Language:

English

Contact:

MerckMedia:Pamela Eisele, [phone]orAn Phan, [phone]orInvestor:Joseph Romanelli, (908) 740-1986orJustin Holko, [phone]

Ticker Slug:

Ticker: MRK Exchange: NYSE

read more

Source: Merck.com - Corporate News - July 22, 2015 Category: Pharmaceuticals Tags: Oncology Newsroom Prescription Medicine News Corporate News Latest News Source Type: news